Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding.
CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly statistically significant improvement in coronary flow reserve and.
Q4 2019 Caladrius Biosciences Inc Earnings Call
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
BASKING RIDGE, N.J., Feb. 27, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company.
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
BASKING RIDGE, N.J., Jan. 07, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company.
BASKING RIDGE, N.J., May 06, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the.
BASKING RIDGE, N.J., May 14, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the.
NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Caladrius Biosciences, Inc. (CLBS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM ...
The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their NJ NOLs and research and development tax credits to unrelated qualifying corporations. “The ability to convert our NJ NOLs into non-dilutive capital is an exciting development for Caladrius, especially in these challenging financial times, and we appreciate the NJEDA’s commitment to supporting research and development for small New Jersey-based companies,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease.
Company founder Robert Coates becomes Executive Chairman Houston, Texas--(Newsfile Corp. - March 17, 2020) - Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that its Board of Directors has appointed Gregory B. Brown, MD, as Chief Executive Officer. He currently serves and will remain on the Memgen board of directors. The company also announced that Robert Coates, PhD, founder and prior Chief Executive Officer, will become Executive Chairman."Having seen the scientific capability ...
BASKING RIDGE, N.J., April 23, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the.
Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,081,083 shares of common stock. The closing of the offering is expected to occur on or about April 27, 2020, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Caladrius management will host a conference call for investors beginning at 4:30 p.m. (ET) on Thursday, May 7, 2020 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing 866-595-8403 (domestic) or 706-758-9979 (international) and referencing conference ID number 8869677. The conference call will also be webcast live under the Investors section of the Company's website at www.caladrius.com.
Anyone researching Caladrius Biosciences, Inc. (NASDAQ:CLBS) might want to consider the historical volatility of the...
Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock. The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering.
Under the purchase agreement, Caladrius has also issued to the investors unregistered warrants to purchase up to an aggregate of 1,081,083 shares of common stock. The warrants have an exercise price equal to $2.25 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.
Q1 2020 Caladrius Biosciences Inc Earnings Call
BASKING RIDGE, N.J., Feb. 03, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company.